Related Experiment Video
Updated: Jul 8, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Targeting Src homology phosphatase 2 ameliorates mouse diabetic nephropathy by attenuating ERK/NF-κB pathway-mediated
Che Yu1,2,3, Zhuo Li1, Cuili Nie4
1Department of Nephrology, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Abstract:
Renal inflammation is a pivotal mechanism underlying the pathophysiology of diabetic nephropathy (DN). The Src homology phosphatase 2 (SHP2) has been demonstrated to be linked to diabetes-induced inflammation, yet its roles and explicit molecular mechanisms in DN remain unexplored. Here, we report that SHP2 activity is upregulated in both DN patients and db/db mice. In addition, pharmacological inhibition of SHP2 with its specific inhibitor PHPS1 alleviates DN in db/db mice and attenuates renal inflammation. In vitro, PHPS1 administration prevents inflammatory responses in HK-2 cells stimulated by high glucose (HG). Mechanistically, PHPS1 represses HG-induced activation of the proinflammatory ERK/NF-κB signaling pathway, and these inhibitory effects are blocked in the presence of an ERK specific inhibitor, hence demonstrating that PHPS1 suppresses ERK/NF-κB pathway-mediated inflammation. Moreover, PHPS1 retards ERK/NF-κB pathway activation in db/db mice, and histologically, SHP2 activity is positively correlated with ERK/NF-κB activation in DN patients. Taken together, these findings identify SHP2 as a potential therapeutic target and show that its pharmacological inhibition might be a promising strategy to mitigate DN. Video Abstract.
Insights
Inhibition of SHP2 (Src homology phosphatase 2) reduces kidney inflammation in diabetic nephropathy (DN). This study highlights SHP2 as a potential therapeutic target for DN treatment.
Area of Science:
- Biochemistry
- Immunology
- Pathophysiology
Background:
- Diabetic nephropathy (DN) involves significant renal inflammation.
- The role of Src homology phosphatase 2 (SHP2) in DN pathogenesis is not well understood.
- SHP2 is implicated in diabetes-related inflammation.
Discussion:
- SHP2 activity is elevated in DN patients and db/db mice.
- Pharmacological inhibition of SHP2 using PHPS1 ameliorates DN and reduces renal inflammation in mice.
- PHPS1 treatment inhibits high glucose-induced inflammatory responses in HK-2 cells.
Key Insights:
- SHP2 inhibition suppresses the ERK/NF-κB signaling pathway, a key mediator of inflammation.
- PHPS1 effectively blocks the activation of the ERK/NF-κB pathway in both in vitro and in vivo models of DN.
- SHP2 activity positively correlates with ERK/NF-κB activation in DN patients.
Outlook:
- SHP2 represents a promising therapeutic target for diabetic nephropathy.
- Pharmacological inhibition of SHP2 offers a potential strategy for mitigating DN progression.
- Further research into SHP2-targeted therapies could lead to novel treatments for DN.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
PI3K/mTOR/AKT Signaling Pathway